Psoriatic Arthritis – Global Drug Forecast and Market Analysis to 2028

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Psoriatic arthritis (PsA) is a chronic form of arthropathy commonly associated with psoriasis. Patients are evaluated on five disease domains: peripheral arthritis, axial disease, enthesitis, dactylitis, and nail and skin involvement. Due to the heterogeneity of clinical symptoms, PsA can be difficult to diagnose and treat.
Current therapies for disease management include conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs), injectable immuno-suppressants and oral small molecule therapies. Of these, intravenous and subcutaneous therapies targeting tumor necrosis factor (anti-TNFs) have been the gold standard of care for almost 20 years. However, other mechanisms of action have gained traction in recent years. Over the forecast period, market growth is expected to be driven primarily by the approval and launch of five pipeline therapies. However, this growth will likely be curtailed by the erosion of branded agents sales by biosimilars and generics in the second half of the forecast period.
KEY QUESTIONS ANSWERED
Which unmet needs are limiting the treatment of PsA in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan)?
What strategies can the pharmaceutical industry employ to increase treatment rates for PsA? How should these strategies differ across different geographical markets?
What effect will the launch of biosimilars and generics have on the sales of branded agents? What can drug manufacturers do in order to ensure the success of their biosimilars?
What are the main R&D trends in the PsA market and which companies are leading the way? Are there major differences in the mechanisms of action used by therapies in late-stage versus early-stage clinical development?

Scope

Overview of PsA including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

Topline PsA market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.

Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting PsA therapeutics sales in the 7MM.

Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.

Analysis of the current and future market competition in the global PsA therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

The greatest drivers of growth in the global PsA market include the launch of five new pipeline therapies during the forecast period and a steadily climbing diagnosed prevalence in many 7MM countries.

The main barriers to growth in the PsA market include low diagnostic and treatment rates as well as low patient compliance and persistence.

Among the late-stage pipeline products, two are injectable anti-interleukin therapies and three are oral Janus Kinase (JAK) inhibitors.

The most important unmet needs in the PsA market are increased access to therapies as well as therapies that can target the multiple disease domains.

Reasons to Buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.

Develop business strategies by understanding the trends shaping and driving the global PsA therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global PsA market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Track drug sales in the global PsA therapeutics market from 2018-2028.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

AbbVie
Pfizer
Johnson & Johnson (J&J)
Bristol-Myers Squibb
UCB Pharma
Amgen
Novartis
Eli Lilly
Gilead
Galapagos
Sun Pharma
Kyowa Hakko Kirin

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Psoriatic Arthritis: Executive Summary

2.1 PsA Market to Experience Moderate Growth from 2018–2028

2.2 Oral Therapeutics Dominate the Late-Stage PsA Pipeline

2.3 Opportunities Remain for More Cost-Effective and Targeted Treatments

2.4 Convenient and Affordable Pipeline Agents Poised to Perform Well in a Crowded PsA Market

2.5 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 Etiology

4.1.2 Pathophysiology

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.4 Forecast Methodology

5.4.1 Sources Used

5.4.2 Forecast Assumptions and Methods

5.4.3 Sources Not Used

5.5 Epidemiological Forecast for Psoriatic Arthritis (2018-2028)

5.5.1 Diagnosed Incident Cases of PsA

5.5.2 Diagnosed Prevalent Cases of PsA

5.5.3 Sex-Specific Diagnosed Prevalent Cases of PsA

5.5.4 Age-Specific Diagnosed Prevalent Cases of PsA

5.5.5 Diagnosed Prevalent Cases of PsA by Severity

5.5.6 Diagnosed Prevalent Cases of PsA with Psoriasis

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of Analysis

5.6.3 Strengths of Analysis

6 Disease Management

6.1 Diagnosis and Treatment Overview

6.1.1 Diagnostic Scales

6.1.2 Treatment Guidelines by Market

6.2 US

6.3 5EU

6.4 Japan

7 Competitive Assessment

7.1 Overview

7.1.1 TNF Inhibitors

7.1.2 IL-17 Inhibitors

7.1.3 IL-23 Inhibitors

7.1.4 Janus Kinase Inhibitors

7.1.5 Other Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs

7.2 Biosimilars

8 Unmet Needs and Opportunity Assessment

8.1 Overview

8.2 Increased Clinician Awareness of PsA

8.3 Earlier and More Accurate PsA Diagnoses

8.4 Improved Drug Safety and Efficacy Across All Disease Domains

8.5 Improved Access to Therapies

9 Pipeline Assessment

9.1 Overview

9.1.1 IL-17 Inhibitors

9.1.2 IL-23 Inhibitors

9.1.3 JAK Inhibitors

9.2 Promising Drugs in Clinical Development

9.3 Other Drugs in Development

10 Current and Future Players

10.1 Overview

10.2 Trends in Corporate Strategy

10.3 AbbVie

10.4 Pfizer

10.5 Johnson & Johnson

10.6 Bristol-Myers Squibb

10.7 UCB

10.8 Amgen

10.9 Novartis

10.10 Eli Lilly

10.11 Gilead

10.12 Sun Pharma

10.13 Kyowa Hakko Kirin

11 Market Outlook

11.1 Global Markets

11.1.1 Forecast

11.1.2 Drivers and Barriers – Global Issues

11.2 US

11.2.1 Forecast

11.2.2 Key Events

11.2.3 Drivers and Barriers

11.3 5EU

11.3.1 Forecast

11.3.2 Key Events

11.3.3 Drivers and Barriers

11.4 Japan

11.4.1 Forecast

11.4.2 Key Events

11.4.3 Drivers and Barriers

12 Appendix

12.1 Bibliography

12.2 Abbreviations

12.3 Methodology

12.3.1 Forecasting Methodology

12.3.2 Diagnosed Patients

12.3.3 Percent Drug-Treated Patients

12.3.4 Drugs Included in Each Therapeutic Class

12.3.5 Launch and Patent Expiry Dates

12.3.6 General Pricing Assumptions

12.3.7 Individual Drug Assumptions

12.3.8 Generic Erosion

12.3.9 Pricing of Pipeline Agents

12.4 Primary Research – KOLs and Payers Interviewed for This Report

12.4.1 KOLs

12.4.2 Payers

12.5 Primary Research – Prescriber Survey

12.6 About the Authors

12.6.1 Analysts

12.6.2 Therapy Area Director

12.6.3 Epidemiologist

12.6.4 Managing Epidemiologist

12.6.5 Global Director of Therapy Analysis and Epidemiology

12.6.6 Global Head and EVP of Healthcare Operations and Strategy

12.7 About GlobalData

12.8 Contact Us

12.9 Disclaimer

Table

Table 1: Psoriatic Arthritis: Key Metrics in the 7MM

Table 2: Risk Factors and Comorbidities for PsA

Table 3: Classification Systems in PsA

Table 4: Treatment Guidelines for PsA by Market

Table 5: Country Profile – US

Table 6: Country Profile – 5EU

Table 7: Country Profile – Japan

Table 8: Leading Treatments for Psoriatic Arthritis, 2019

Table 9: Marketed Biosimilars for PsA, 2019

Table 10: 7MM, Non-Responsive Patients by Drug Class, All Severities, 2019

Table 11: AbbVie’s Disease Portfolio Assessment, 2020

Table 12: Pfizer’s Disease Portfolio Assessment, 2020

Table 13: J&J’s Disease Portfolio Assessment, 2020

Table 14: Bristol-Myer’s Squibb Disease Portfolio Assessment, 2020

Table 15: UCB’s Disease Portfolio Assessment, 2020

Table 16: Amgen’s Disease Portfolio Assessment, 2020

Table 17: Novartis’ Disease Portfolio Assessment, 2020

Table 18: Eli Lilly’s Disease Portfolio Assessment, 2020

Table 19: Gilead Disease Portfolio Assessment, 2020

Table 20: SunPharma’s Disease Portfolio Assessment, 2020

Table 21: Kyowa Hakko Kirin’s Disease Portfolio Assessment, 2020

Table 22: PsA Market – Global Drivers and Barriers, 2018–2028

Table 23: Key Events Impacting Sales for PsA in the US, 2018–2028

Table 24: PsA Market – Drivers and Barriers in the US, 2018–2028

Table 25: Key Events Impacting Sales for PsA in the 5EU, 2018–2028

Table 26: PsA Market – Drivers and Barriers in the 5EU, 2018–2028

Table 27: Key Events Impacting Sales for PsA in Japan, 2018–2028

Table 28: Psoriatic Arthritis Market – Global Drivers and Barriers in Japan, 2018–2028

Table 29: Key Historical and Projected Launch Dates for PsA

Table 30: Key Projected Patent Expiry Dates for PsA

Table 31: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figures

Figure 1: Global Sales Forecast by Country for PsA in 2018 and 2028

Figure 2: Analysis of the Company Portfolio Gap in PsA During the Forecast Period

Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents for PsA, 2020

Figure 4: Key Molecular Targets in Psoriatic Arthritis

Figure 5: 7MM, Diagnosed Prevalence of PsA, Men and Women, Ages ≥18 Years, 2008

Figure 6: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of PsA

Figure 7: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of PsA

Figure 8: 7MM, Diagnosed Incident Cases of PsA, Men and Women, Ages ≥18 Years

Figure 9: 7MM, Diagnosed Prevalent Cases of PsA, Men and Women, Ages ≥18 Years

Figure 10: 7MM, Diagnosed Prevalent Cases of PsA by Sex, Ages ≥18 Years, 2018

Figure 11: 7MM, Diagnosed Prevalent Cases of PsA by Age, Men and Women, 2018

Figure 12: 7MM, Diagnosed Prevalent Cases of PsA by Severity, Men and Women, Ages ≥18 Years, 2018

Figure 13: 7MM, Diagnosed Prevalent Cases of PsA with Psoriasis, Men and Women, Ages ≥18 Years

Figure 14: EULAR Treatment Algorithm for Psoriatic Arthritis, 2015

Figure 15: GRAPPA Treatment Algorithm for Psoriatic Arthritis

Figure 16: Unmet Needs and Opportunities in PsA, 2019

Figure 17: Overview of the Development Pipeline in Psoriatic Arthritis

Figure 18: Key Phase II/III Trials for the Promising PsA Pipeline Agents

Figure 19: Competitive Assessment of the Late-Stage Pipeline Agents for PsA, 2020

Figure 20: Analysis of the Company Portfolio Gap in PsA During the Forecast Period

Figure 21: Global (7MM) Sales Forecast by Country for PsA in 2018 and 2028

Figure 22: Sales Forecast for PsA in the US, by Class, 2018 and 2028

Figure 23: Sales Forecast for PsA in the 5EU, by Class, 2018 and 2028

Figure 24: Sales Forecast for PsA in Japan, by Class, 2018 and 2028

Frequently asked questions

Psoriatic Arthritis – Global Drug Forecast and Market Analysis to 2028 thematic reports
Currency USD
$10,995

Can be used by individual purchaser only

$32,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Psoriatic Arthritis – Global Drug Forecast and Market Analysis to 2028 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Psoriatic Arthritis – Global Drug Forecast and Market Analysis to 2028 in real time.

  • Access a live Psoriatic Arthritis – Global Drug Forecast and Market Analysis to 2028 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.